Audrey Broussy - Publications

Erratum: Efficacy and safety of SENS-501, a dual-AAV otoferlin gene therapy, for DFNB9 congenital deafness.

Journal: Molecular therapy. Advances

Published: August 07, 2026

Efficacy and safety of SENS-501, a dual-AAV otoferlin gene therapy, for DFNB9 congenital deafness.

Journal: Molecular therapy. Advances

Published: December 04, 2025

SENS-401 Effectively Reduces Severe Acoustic Trauma-Induced Hearing Loss in Male Rats With Twice Daily Administration Delayed up to 96 hours.

Journal: Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology

Published: December 21, 2018

Noise-induced trauma produces a temporal pattern of change in blood levels of the outer hair cell biomarker prestin.

Journal: Hearing research

Published: June 28, 2018

Oral Administration of Clinical Stage Drug Candidate SENS-401 Effectively Reduces Cisplatin-induced Hearing Loss in Rats.

Journal: Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology

Published: August 11, 2017

Correlation between afferent rearrangements and behavioral deficits after local excitotoxic insult in the mammalian vestibule: a rat model of vertigo symptoms.

Journal: Disease models & mechanisms

Published: January 06, 2016

Ondansetron reduces lasting vestibular deficits in a model of severe peripheral excitotoxic injury.

Journal: Journal of vestibular research : equilibrium & orientation

Published: November 02, 2013

Histamine H4 receptor antagonists as potent modulators of mammalian vestibular primary neuron excitability.

Journal: British journal of pharmacology

Published: May 26, 2012